Odimma Therapeutics https://validator.w3.org/feed/docs/rss2.html Odimma Therapeutics Showcases Its Personalized Immunotherapy Platform at the 5th Neoantigen Summit Europe Home Company Legal Notice Odimma Therapeutics Recognized Among Europe’s Most Innovative Biotech Companies at BioFIT 2022 €2 Million Financing Secured to Advance ODI-2001 Toward First-in-Human Clinical Trials Odimma Therapeutics Secures €2 Million to Advance Its Personalized Cancer Immunotherapy Platform Odimma Therapeutics Named Among France’s “100 Start-ups to Invest in 2021” ABL and Odimma Therapeutics Partner to Advance Personalized Cancer Immunotherapy Odimma Therapeutics Establishes Its Headquarters at PH8 Health Innovation Hub Odimma Therapeutics Selected as a Finalist for WiClub Health #2 Odimma Therapeutics Strengthens Its Platform Through Strategic Partnership with Touchlight Strategic Clinical Collaboration Established with myNEO Odimma Therapeutics present at BIO-Europe Spring 2023 Participation in the SACHS Annual Biotech in Europe Forum 2023 Joining the Paris Saclay Cancer Cluster Oncology Ecosystem Participation in BIO-Europe Spring 2024 in Barcelona Odimma Therapeutics to Present Preclinical ODI-2001 Data at SITC 2024 ODI-2001 Preclinical Data to Be Presented at ESMO 2024 Odimma Therapeutics Selected Among the 10 New Projects Supported by the Paris Saclay Cancer Cluster Odimma Therapeutics Announces First Clinical Trial Application Submission for ODI-2001 Newsroom Programs Contact Platform Technology Terms of Use Odimma Therapeutics Selected for the France 2030 Export Program Awarded the European Commission Seal of Excellence for the ODI Platform Privacy Policy Cookie Policy (EU) ODI-2001 Pharmaceutical Process Approved, Validated and Ready for Clinical Deployment